Emma Puighermanal

Emma Puighermanal is a neuropharmacologist focused on how cannabinoids affect brain function and pathology, particularly for therapeutic use. She earned her PhD in Biomedicine at Pompeu Fabra University (Spain), studying the molecular effects of cannabis exposure. During her postdoctoral work at Valjent Lab (CNRS-INSERM, France), supported by EMBO, Marie Skłodowska-Curie, and NARSAD fellowships, she researched cell type–specific signaling of drugs of abuse. At Quintana Lab (UAB, Spain), she explored cannabinoid therapies for mitochondrial diseases, achieving Orphan Drug Designation. Since 2022, she leads the Puig2 Lab (UAB) with a Ramon y Cajal contract, driving translational cannabinoid research and novel therapeutic development. She has published 30 articles, holds 2 patents, and received 11 awards.